Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Oncology

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2014.59.5058PMID 25605833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

  2015cited by this paper
• Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.

  2014cited by this paper
• PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

  2014cited by this paper
• The immune system and response to HER2-targeted treatment in breast cancer.

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer

  2014cited by this paper
• Adaptive Immune Responses and HER2/neu-Positive Breast Cancer

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Involvement of ImmunePathways in the Therapeutic Response and Outcome in Breast Cancer

  2012cited by this paper
• Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

  2012cited by this paper
• Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

  2011cited by this paper
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

  2010cited by this paper
• Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

  2010cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.

  2010cited by this paper
• The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

  2010cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

  2006cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

  2004cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• New approaches to antibody therapy

  2000cited by this paper

• Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes

  2019cites this paper
• Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

  2017cites this paper
• A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice

  2016cites this paper
• The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy

  2016cites this paper
• Prognostic and predictive immune gene signatures in breast cancer

  2015cites this paper
• A Signature for Trastuzumab Benefit in HER2-Positive Breast Cancer?

  2015cites this paper